A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
Fred Hutchinson Cancer Center
University of Illinois at Chicago
Bayer
UNC Lineberger Comprehensive Cancer Center
Labcorp Corporation of America Holdings, Inc
Intensity Therapeutics, Inc.
Cedars-Sinai Medical Center
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
Cyteir Therapeutics, Inc.
BeiGene
Taproot Health
TopAlliance Biosciences
Memorial Sloan Kettering Cancer Center
Xencor, Inc.
Prelude Therapeutics
Gene Surgery LLC
Cedars-Sinai Medical Center
Presage Biosciences
TransThera Sciences (Nanjing), Inc.
UNICANCER
Corvus Pharmaceuticals, Inc.
M.D. Anderson Cancer Center
Emory University
Genmab
Tempest Therapeutics
Prelude Therapeutics
Quadriga Biosciences, Inc.
Ludwig Institute for Cancer Research
Ludwig Institute for Cancer Research
Roswell Park Cancer Institute
Oncovir, Inc.
Celgene
Eli Lilly and Company
Eli Lilly and Company
Stanford University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Massachusetts General Hospital
Dana-Farber Cancer Institute
Virginia Commonwealth University
Altor BioScience
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Stanford University
Valerio Therapeutics
Valerio Therapeutics